Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Interest Expense: ¥-32.2 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688443 Chongqing Genrix Biopharmaceutical Co Ltd SHSE:688443
66 GF Score
Price ¥21.89
GF Value ¥292.81
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Chongqing Genrix Biopharmaceutical Co Interest Expense?

Chongqing Genrix Biopharmaceutical Co SHSE:688443 -2.15% 66 Interest Expense is ¥-32.2 Mil as of Jun. 2026. GuruFocus rates SHSE:688443 with a GF Score™ of 66/100 and a GF Value™ of ¥292.81 (Possible Value Trap). The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Chongqing Genrix Biopharmaceutical Co's interest expense for the three months ended in Jun. 2026 was ¥ -7.7 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was ¥-32.2 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Chongqing Genrix Biopharmaceutical Co's Operating Income for the three months ended in Jun. 2026 was ¥ -160.3 Mil. Chongqing Genrix Biopharmaceutical Co's Interest Expense for the three months ended in Jun. 2026 was ¥ -7.7 Mil. Chongqing Genrix Biopharmaceutical Co did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Chongqing Genrix Biopharmaceutical Co  (SHSE:688443) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Chongqing Genrix Biopharmaceutical Co's Interest Expense for the three months ended in Jun. 2026 was ¥-7.7 Mil. Its Operating Income for the three months ended in Jun. 2026 was ¥-160.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2026 was ¥948.0 Mil.

Chongqing Genrix Biopharmaceutical Co's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

Chongqing Genrix Biopharmaceutical Co did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Chongqing Genrix Biopharmaceutical Co Interest Expense Historical Data

* Premium members only.

The historical data trend for Chongqing Genrix Biopharmaceutical Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chongqing Genrix Biopharmaceutical Co Interest Expense Chart

Chongqing Genrix Biopharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -32.42 -32.75 -34.99 -28.90 -31.41

Chongqing Genrix Biopharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.78 -7.89 -8.42 -8.14 -7.75
SHSE:688443
66GF Score
Chongqing Genrix Biopharmaceutical Co Ltd SHSE:688443
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chongqing Genrix Biopharmaceutical Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-32.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of ¥-32.2 Mil mean?
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) has a Interest Expense of ¥-32.2 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Chongqing Genrix Biopharmaceutical Co and its competitors.
Is Chongqing Genrix Biopharmaceutical Co's Interest Expense too high?
Chongqing Genrix Biopharmaceutical Co's current Interest Expense is ¥-32.2 Mil. Overall, Chongqing Genrix Biopharmaceutical Co has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chongqing Genrix Biopharmaceutical Co's Interest Expense compare to VRTX and REGN?
Chongqing Genrix Biopharmaceutical Co's Interest Expense of ¥-32.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Chongqing Genrix Biopharmaceutical Co and its competitors. Chongqing Genrix Biopharmaceutical Co's current Interest Expense is ¥-32.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chongqing Genrix Biopharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chongqing Genrix Biopharmaceutical Co (SHSE:688443) is currently considered Possible Value Trap. The stock's GF Value™ is ¥292.81, compared to a current price of ¥21.89 — trading 92.5% below its estimated fair value. The current Interest Expense is ¥-32.2 Mil. Chongqing Genrix Biopharmaceutical Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Chongqing Genrix Biopharmaceutical Co (SHSE:688443), the current Interest Expense is ¥-32.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Overvalued in 2026?

Based on GuruFocus' analysis, Chongqing Genrix Biopharmaceutical Co stock appears to be undervalued. The current stock price of ¥21.89 is trading 92.5% below its estimated GF Value™ of ¥292.81. GuruFocus considers Chongqing Genrix Biopharmaceutical Co to be Possible Value Trap.

Key valuation signals for SHSE:688443:

  • Interest Expense: ¥-32.2 Mil
  • GF Value™: ¥292.81 vs. price of ¥21.89 (92.5% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the SHSE:688443 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chongqing Genrix Biopharmaceutical Co Business Description

Address No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan District, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is a biopharmaceutical company engaged in the research & development, production and sales of antibody drugs. The company's pipeline includes product candidate that targets Autoimmune Diseases, Infectious Diseases, and Oncology.
66GF Score

Get the complete analysis for SHSE:688443

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥21.89
Price
¥292.81
GF Value